





















- et al. Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group. *Am J Obstet Gynecol* 2016;214:424-37.
34. Timmerman D, Amez L, Fischerova D, et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. *BMJ* 2010;341:c6839.
35. Andreotti RF, Timmerman D, Strachowski LM, et al. O-RADS US risk stratification and management system: a consensus guideline from the ACR Ovarian-Adnexal Reporting and Data System Committee. *Radiology* 2020;294:168-85.
36. Elder JW, Pavlik EJ, Long A, et al. Serial ultrasonographic evaluation of ovarian abnormalities with a morphology index. *Gynecol Oncol* 2014;135:8-12.
37. Kaijser J, Sayasneh A, Van Hoorde K, et al. Presurgical diagnosis of adnexal tumours using mathematical models and scoring systems: a systematic review and meta-analysis. *Hum Reprod Update* 2014;20:449-62.
38. Cao L, Wei M, Liu Y, et al. Validation of American College of Radiology Ovarian-Adnexal Reporting and Data System Ultrasound (O-RADS US): analysis on 1054 adnexal masses. *Gynecol Oncol* 2021;162:107-12.
39. Foti PV, Attinà G, Spadola S, et al. MR imaging of ovarian masses: classification and differential diagnosis. *Insights Imaging* 2016;7:21-41.
40. Iyer VR, Lee SI. MRI, CT, and PET/CT for ovarian cancer detection and adnexal lesion characterization. *AJR Am J Roentgenol* 2010;194:311-21.
41. Bast RC Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. *N Engl J Med* 1983;309:883-7.
42. Sölétormos G, Duffy MJ, Othman Abu Hassan S, et al. Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the European Group on Tumor Markers. *Int J Gynecol Cancer* 2016;26:43-51.
43. Carlson KJ, Skates SJ, Singer DE. Screening for ovarian cancer. *Ann Intern Med* 1994;121:124-32.
44. Zapardiel I, Gorostidi M, Ravaggi A, Allende MT, Silveira M, Macuks R. Utility of human epididymis protein 4 serum marker for the detection of adnexal malignancy: a multicentric prospective study. *Eur J Cancer Prev* 2017;26:346-50.
45. Ueland FR, Desimone CP, Seamon LG, et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. *Obstet Gynecol* 2011;117:1289-97.
46. Havrilesky LJ, Dinan M, Sfakianos GP, et al. Costs, effectiveness, and workload impact of management strategies for women with an adnexal mass. *J Natl Cancer Inst* 2014;107:322.
47. Coleman RL, Herzog TJ, Chan DW, et al. Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses. *Am J Obstet Gynecol* 2016;215(1):82.e1-82.e11.
48. van Nagell JR Jr, Miller RW. Evaluation and management of ultrasonographically detected ovarian tumors in asymptomatic women. *Obstet Gynecol* 2016;127:848-58.
49. Modesitt SC, Pavlik EJ, Ueland FR, DePriest PD, Kryscio RJ, van Nagell JR Jr. Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. *Obstet Gynecol* 2003;102:594-9.
50. Bailey CL, Ueland FR, Land GL, et al. The malignant potential of small cystic ovarian tumors in women over 50 years of age. *Gynecol Oncol* 1998;69:3-7.
51. Medeiros LRF, Rosa DD, Bozzetti MC, et al. Laparoscopy versus laparotomy for benign ovarian tumour. *Cochrane Database Syst Rev* 2009;2:CD004751.
52. El Khouly NI, Barr RL, Kim BB, et al. Comparison of robotic-assisted and conventional laparoscopy in the management of adnexal masses. *J Minim Invasive Gynecol* 2014;21:1071-4.
53. Comerci JT Jr, Licciardi F, Bergh PA, Gregori C, Breen JL. Mature cystic teratoma: a clinicopathologic evaluation of 517 cases and review of the literature. *Obstet Gynecol* 1994;84:22-8.
54. Pascual MA, Graupera B, Pedrero C, et al. Long-term results for expectant management of ultrasonographically diagnosed benign ovarian teratomas. *Obstet Gynecol* 2017;130:1244-50.
55. Hart RJ, Hickey M, Maouris P, Buckett W. Excisional surgery versus ablative surgery for ovarian endometriomata. *Cochrane Database Syst Rev* 2008;2:CD004992.
56. Younis JS, Shapso N, Ben-Sira Y, Nelson SM, Izhaki I. Endometrioma surgery — a systematic review and meta-analysis of the effect on antral follicle count and anti-Müllerian hormone. *Am J Obstet Gynecol* 2022;226(1):33-51.e7.
57. Goodman LR, Goldberg JM, Flyckt RL, Gupta M, Harwalker J, Falcone T. Effect of surgery on ovarian reserve in women with endometriomas, endometriosis and controls. *Am J Obstet Gynecol* 2016;215(5):589.e1-589.e6.
58. Legendre G, Catala L, Morinière C, et al. Relationship between ovarian cysts and infertility: what surgery and when? *Fertil Steril* 2014;101:608-14.
59. Engelen MJA, Kos HE, Willemse PHB, et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. *Cancer* 2006;106:589-98.
60. Earle CC, Schrag D, Neville BA, et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. *J Natl Cancer Inst* 2006;98:172-80.
61. Giede KC, Kieser K, Dodge J, Rosen B. Who should operate on patients with ovarian cancer? An evidence-based review. *Gynecol Oncol* 2005;99:447-61.
62. Carney ME, Lancaster JM, Ford C, Tsodikov A, Wiggins CL. A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not? *Gynecol Oncol* 2002;84:36-42.
63. Webb MJ, Decker DG, Mussey E, Williams TJ. Factor influencing survival in stage I ovarian cancer. *Am J Obstet Gynecol* 1973;116:222-8.
64. Junor EJ, Hole DJ, McNulty L, Mason M, Young J. Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. *Br J Obstet Gynaecol* 1999;106:1130-6.
65. Im SS, Gordon AN, Buttin BM, et al. Validation of referral guidelines for women with pelvic masses. *Obstet Gynecol* 2005;105:35-41.
66. Heo SH, Kim JW, Shin SS, et al. Review of ovarian tumors in children and adolescents: radiologic-pathologic correlation. *Radiographics* 2014;34:2039-55.
67. Zhang M, Jiang W, Li G, Xu C. Ovarian masses in children and adolescents — an analysis of 521 clinical cases. *J Pediatr Adolesc Gynecol* 2014;27(3):e73-e77.
68. Oltmann SC, Garcia N, Barber R, Huang R, Hicks B, Fischer A. Can we preoperatively risk stratify ovarian masses for malignancy? *J Pediatr Surg* 2010;45:130-4.
69. Renaud EJ, Sømme S, Islam S, et al. Ovarian masses in the child and adolescent: an American Pediatric Surgical Association Outcomes and Evidence-Based Practice Committee systematic review. *J Pediatr Surg* 2019;54:369-77.
70. Stankovic ZB, Bjelica A, Djukic MK, Savic D. Value of ultrasonographic detection of normal ovarian tissue in the differential diagnosis of adnexal masses in pediatric patients. *Ultrasound Obstet Gynecol* 2010;36:88-92.
71. Aziz D, Davis V, Allen L, Langer JC. Ovarian torsion in children: is oophorectomy necessary? *J Pediatr Surg* 2004;39:750-3.
72. Webb KE, Sakhel K, Chauhan SP, Abuhamad AZ. Adnexal mass during pregnancy: a review. *Am J Perinatol* 2015;32:1010-6.
73. Rajaram S, Exley CE, Fairlie F, Matthews S. Effect of antenatal iodinated contrast agent on neonatal thyroid function. *Br J Radiol* 2012;85(1015):e238-e242.
74. American College of Radiology. ACR-SPR practice parameter for imaging pregnant or potentially pregnant adolescents and women with ionizing radiation. 2018 (<https://www.acr.org/-/media/acr/files/practice-parameters/pregnant-pts.pdf>).
75. Ball E, Waters N, Cooper N, et al. Evidence-based guideline on laparoscopy in pregnancy: commissioned by the British Society for Gynaecological Endoscopy (BSGE) endorsed by the Royal College of Obstetricians & Gynaecologists (RCOG). *Facts Views Vis Obgyn* 2019;11:5-25.

Copyright © 2022 Massachusetts Medical Society.